Saturday November 21 2009 | Biotechnology feed | All feeds
|
|
|
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive AssessmentMonday 26th of October 2009 15:14-- A focus on "engineered" antibodiesMonoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing improved mAb-based products to the market, concentrating on those used for therapeutic applications. It surveys the latest technologies being applied to the development of these compounds and profiles the major companies, drugs, and projects. It then draws conclusions about the future market potential for mAbs and discusses the major challenges faced by the industry. The biotech industry devoted years to reducing the immunogenicity of mAbs, developing the technologies--detailed in this report--to progress from chimeric, to humanized, to fully human antibodies. These succeeding generations of mAbs have demonstrated incremental improvements in safety and activity, and the industry is currently in the middle of a major shift toward humanized and human products. Much work has also been done on altering antibodies' outward form to boost their efficacy, enabling them to more readily penetrate tumors, enhancing their ability to stimulate beneficial immune responses, or otherwise improving their characteristics. Into this realm fall such constructions as antibody fragments, diabodies, synthetic antibodies, bispecific antibodies, and antibody conjugates. This report looks at some of the engineered forms of antibodies and the companies that are leading the way in this research. Other complementary technologies, such as PEGylation and glycosylation, are also presented. Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment presents an analysis for the current state of mAb drug development. It identifies more than 250 therapeutic products now in clinical trials, which are largely concentrated in the areas of cancer, immunological and inflammatory diseases, as well as infectious diseases. Beyond these, hundreds more candidates are at the preclinical stage of development. Reviewed here are the products that are already available, those in clinical development, and those still at the preclinical stage that are likely to play an important role in the advancement of the field. Please note, this report is delivered as a zip file. Executive Summary Chapter 1 BACKGROUND AND SCIENTIFIC OVERVIEW: ANTIBODIES AND MONOCLONAL ANTIBODIES 1.1. What Is an Antibody? 1.2. What Is a Monoclonal Antibody? Chapter 2 CURRENT AND EMERGING TECHNOLOGIES: IMPROVING MONOCLONAL ANTIBODY DESIGN AND PRODUCTION 2.1. Key Breakthroughs in the First 35 Years of Monoclonal Antibody Development Murine-Derived Monoclonal Antibodies Chimeric Monoclonal Antibodies Humanized Monoclonal Antibodies Fully Human Monoclonal Antibodies Antibody Fragments Antibody Conjugates 2.2. Monoclonal Antibody Libraries and Display Technologies Phage Display MedImmune (AstraZeneca) Dyax Crucell MorphoSys Affitech Biosite (Inverness Medical Innovations) Affimed Therapeutics XOMA Ribosome Display MedImmune (AstraZeneca) Discerna Other Library-Based Technologies Alexion Pharmaceuticals BioInvent International viii -- www.InsightPharmaReports.com -- Reproduction prohibited Table of Contents Adimab MSM Protein Technologies Vaccinex Morphotek (Eisai Corp. of North America) AnaptysBio Sorrento Therapeutics 2.3. Other Technologies for Designing Monoclonal Antibodies Techniques for Improving Hybridoma Production Abeome New Techniques for Generating Animal-Derived Monoclonal Antibodies GENOVAC (Aldevron) Epitomics North Coast Biologics Xori Chiome Bioscience Humanization Technology Abmaxis (Merck) Arana Therapeutics MRC Technology ImmunoGen KaloBios Pharmaceuticals PDL BioPharma XOMA Antitope Xencor Massachusetts Institute of Technology Transgenic Mice Amgen Medarex AVANIR Pharmaceuticals Regeneron Pharmaceuticals Human Hybridoma Technology Morphotek (Eisai Corp. of North America) Patrys Kenta Biotech 2.4. Alternative Antibody Formats Antibody Fragments ESBATech MacroGenics Genmab Synthetic Antibodies Ablynx Affibody Domantis (GlaxoSmithKline) AdAlta Enzon Pharmaceuticals/Micromet Arana Therapeutics Bispecific Antibodies Elusys Therapeutics Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment Micromet TRION Pharma Affimed Therapeutics Affitech/Pharmexa Biotecnol Other Antibodies That Enhance Effector Function BioWa MacroGenics Tolerx Vaccibody InNexus Biotechnology Xencor 2.5. Antibody Conjugates Antibody-Radioisotope Conjugates Affibody PBL Therapeutics Aduro BioTech Antibody-Drug Conjugates Medarex HERMES Biosciences Celldex Therapeutics Scancell Paladin Labs Antibody-Toxin Conjugates 2.6. Technologies for Improving Monoclonal Antibody Characteristics Protein Engineering Applied Molecular Evolution (Eli Lilly) Arana Therapeutics Morphotek MilleGen/Accuro Biologics Facet Biotech Xencor Merus Algonomics f-star PEGylation Alternatives to PEGylation Glycosylation GlycArt (Roche) GlycoFi (Merck) Glycotope Synageva BioPharma LFB Alternative Modes of Administration Altus Pharmaceuticals Baxter BioPharma Solutions Chapter 3 MARKETED AND EMERGING MONOCLONAL ANTIBODIES: PRESENT AND FUTURE THERAPEUTICS 3.1. Approved Therapeutic Monoclonal Antibodies Profiles of Therapeutic Monoclonal Antibodies Approved for Marketing Orthoclone OKT3 (Muromonab-CD3) (1986) ReoPro (Abciximab) (1994) Rituxan (Rituximab) (1997) Zenapax (Daclizumab) (1997) Simulect (Basiliximab) (1998) Synagis (Palivizumab) (1998) Remicade (Infliximab) (1998) Herceptin (Trastuzumab) (1998) Mylotarg (Gemtuzumab Ozogamicin) (2000) Campath (Alemtuzumab) (2001) Zevalin (Ibritumomab Tiuxetan) (2002) Humira (Adalimumab) (2002) Xolair (Omalizumab) (2003) Bexxar (Tositumomab) (2003) Raptiva (Efalizumab) (2003) Erbitux (Cetuximab) (2004) Avastin (Bevacizumab) (2004) Tysabri (Natalizumab) (2006) Lucentis (Ranibizumab) (2006) Vectibix (Panitumumab) (2006) Soliris (Eculizumab) (2007) Cimzia (Certolizumab Pegol) (2008) Ilaris (Canakinumab) (2009) 3.2. Monoclonal Antibodies in Development for Cancer Unconjugated Monoclonal Antibodies for Cancer Genmab Medarex Biogen Idec Genentech Human Genome Sciences Pfizer Wilex Immunomedics ImClone Systems (Eli Lilly) Morphotek (Eisai Corp. of North America) Antisoma Micromet UCB AVEO Pharmaceuticals Lpath Northwest Biotherapeutics Anti-idiotype Monoclonal Antibodies for Cancer Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment Menarini Group Onyvax Conjugated Monoclonal Antibodies for Cancer Active Biotech Antisoma ImmunoGen Immunomedics MedImmune Seattle Genetics Merck Serono Celldex Therapeutics/Curagen 3.3. Monoclonal Antibodies in Development for Immunological Diseases Human Genome Sciences Novartis UCB Amgen Biogen Idec/Genentech MedImmune Genmab Millennium Pharmaceuticals (Takeda Pharmaceutical) Medarex NovImmune BioTie Therapies Micromet ZymoGenetics/Novo Nordisk Glenmark Pharmaceuticals CSL LigoCyte Pharmaceuticals Sanofi-Aventis/Kyowa Hakko Kirin 3.4. Monoclonal Antibodies in Development for Infectious Diseases Novartis MedImmune Human Genome Sciences Taimed Biologics Medarex Elusys Therapeutics Emergent BioSolutions Crucell Progenics Pharmaceuticals Roche Genmab Theraclone Sciences iBioPharma 3.5. Monoclonal Antibodies in Development for Cardiovascular Diseases Ablynx ThromboGenics/BioInvent International Affimed Therapeutics Table of Contents Lexicon Pharmaceuticals 3.6. Other Therapeutic Antibodies in Development Amgen Elan/Wyeth Eli Lilly Pfizer Others Chapter 4 BUSINESS AND STRATEGIC OUTLOOK: MARKET POTENTIAL FOR MONOCLONAL ANTIBODIES AND TRENDS IN THE FIELD 4.1. General Trends 4.2. The Market for Therapeutic Monoclonal Antibodies Cancer: Solid Tumors Cancer: Non-Hodgkin's Lymphoma Immune and Inflammatory Diseases Transplant Rejection Rheumatoid Arthritis Crohn's Disease Psoriasis Lupus Multiple Sclerosis Asthma Other Emerging Markets Age-Related Macular Degeneration HIV Alzheimer's Disease Chapter 5 CHI INSIGHT PHARMA REPORTS MONOCLONAL ANTIBODIES SURVEY--JULY 2009 References Company Index with Web Addreses Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment Tables Table 3.1. FDA-Approved Therapeutic Monoclonal Antibodies Table 3.2. Unconjugated Monoclonal Antibodies in Clinical Trials for Cancer Table 3.3. Conjugated Monoclonal Antibodies in Clinical Trials for Cancer Table 3.4. Monoclonal Antibodies in Clinical Trials for Immunological Diseases Table 3.5. Monoclonal Antibodies in Clinical Trials for Infectious Diseases Table 3.6. Monoclonal Antibodies in Clinical Trials for Cardiovascular Diseases Table 3.7. Other Therapeutic Monoclonal Antibodies in Clinical Development Table 4.1. Worldwide Sales of Therapeutic Monoclonal Antibodies,2007 and 2008 Table 4.2. Estimated New Cancer Cases in United States, Total and Selected Types, 2009 Figures Figure 1.1. Structure of an Antibody Figure 2.1. Monoclonal Antibody Production Figure 2.2. Antibody Engineering Figure 2.3. Engineered Forms of Antibodies Figure 1A. Please classify your organization Figure 2A. Focus of Respondents' Organizations Figure 3A. Professional Responsibilities of Respondents Figure 4A. Changes in mAb Pipelines Figure 5A. Magnitude of Increase in mAb Pipelines Figure 6A. Recent Changes in Level of Activity Related to mAbs Figure 7A. Future Changes in Level of Activity Related to mAbs Figure 8A. Rate of New mAb Approvals Figure 9A. Challenges to mAb Development Figure 10A. Key Technologies Figure 11A. Future Improvements to mAbs Figure 12A. Relevant Disease Areas To order this report: Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment http://www.reportlinker.com/p0156557/Reportlinker-Adds-Monoclonal-Antibodies-Pipeline-Analysis-and-Competitive-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire More market research reports here!
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker Browse other news from this organisation: Reportlinker Source PR Newswire  |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
